Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Treatment of modifiable risk factors for foot ulceration in persons with diabetes: a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Guidelines on the prevention of foot ulcers in persons with diabetes (IWGDF 2019 update)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Glucose homeostasis in statin users-The LIFESTAT study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Oral insulin does not alter gut microbiota composition of NOD mice

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Risk Factors for Being Seronegative following SARS-CoV-2 Infection in a Large Cohort of Health Care Workers in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Socioeconomic position and prognosis in premenopausal breast cancer: a population-based cohort study in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Hemoglobin A1c-levels and subsequent risk of depression in individuals with and without diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Cardiovascular risk management: A nationwide register-based study of patterns and secular changes of discontinuation prior to death

    Publikation: KonferencebidragKonferenceabstrakt til konferenceForskningpeer review

Vis graf over relationer
BACKGROUND: The cardiovascular safety, including risk of myocardial infarction (MI), of individual sulfonylureas (SUs) may differ. It remains uncertain whether treatment with individual SUs influences prognosis following MI. METHODS: We conducted a nationwide population-based follow-up study among all Danish patients hospitalized with first-time MI from 1996 to 2004. From the national health databases, we identified 3930 MI patients who used SUs at the time of admission. We computed mortality rates and rates of MI and heart failure readmission according to type of SU and used Cox's proportional hazards regression analysis to compute hazard ratios (HRs) as estimates of relative risk controlling for differences in prognostic covariates. RESULTS: The 30-day and 1-year mortality after MI among SU users was 22.0% and 35.3%, respectively. We found no substantial differences in 30-day and 1-year mortality among users of different SUs. Use of gliclazide in monotherapy showed a trend towards lower mortality; adjusted HR of 1-year mortality 0.70 (95% CI: 0.48-1.00). Users of the different SUs appeared to have similar risks of new MI and heart failure following MI. CONCLUSIONS: The prognosis after MI was not substantially influenced by the choice of SU.
OriginalsprogEngelsk
TidsskriftDiabetes - Metabolism: Research and Reviews (Print Edition)
Vol/bind25
Udgave nummer6
Sider (fra-til)515-522
Antal sider8
ISSN1520-7552
DOI
StatusUdgivet - 2009

ID: 64965469